Cargando…

Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland

Objective: The present study investigates the use expectations, prevalence and frequency of neuroenhancement drug (ND) use among the Swiss male population, separating college students from others. Methods: Young Swiss men were invited to participate in the Cohort Study on Substance Use Risk Factors....

Descripción completa

Detalles Bibliográficos
Autores principales: Deline, Stéphane, Baggio, Stéphanie, Studer, Joseph, N’Goran, Alexandra A., Dupuis, Marc, Henchoz, Yves, Mohler-Kuo, Meichun, Daeppen, Jean-Bernard, Gmel, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987019/
https://www.ncbi.nlm.nih.gov/pubmed/24625621
http://dx.doi.org/10.3390/ijerph110303032
_version_ 1782311814924599296
author Deline, Stéphane
Baggio, Stéphanie
Studer, Joseph
N’Goran, Alexandra A.
Dupuis, Marc
Henchoz, Yves
Mohler-Kuo, Meichun
Daeppen, Jean-Bernard
Gmel, Gerhard
author_facet Deline, Stéphane
Baggio, Stéphanie
Studer, Joseph
N’Goran, Alexandra A.
Dupuis, Marc
Henchoz, Yves
Mohler-Kuo, Meichun
Daeppen, Jean-Bernard
Gmel, Gerhard
author_sort Deline, Stéphane
collection PubMed
description Objective: The present study investigates the use expectations, prevalence and frequency of neuroenhancement drug (ND) use among the Swiss male population, separating college students from others. Methods: Young Swiss men were invited to participate in the Cohort Study on Substance Use Risk Factors. A total of 5,967 participants responded to questions on six types of NDs (wakefulness medication, antidepressants, Alzheimer’s disease medication, Parkinson’s disease medication, attention deficit-hyperactivity disorder (ADHD) medication, and beta-blockers). The frequency of use depending on five expectations (to enhance wakefulness, attention, memory, concentration and stress reduction) was analyzed for a twelve-month period. Results: (1) About 3% of the sample indicated use of at least one ND; (2) ADHD medication was the most prevalent; (3) The type of ND preferred differed depending on academic status (4). Quantitatively, over the year, college student users used ND much less frequently than other users. Conclusions: Prevalence of ND use is low in Switzerland relative to other countries such as the United States. Patterns of ND use differed depending on academic status, suggesting that while college student ND users tended to do so rarely (probably to enhance cognitive abilities for exams), non-college male users used other NDs more frequently (probably to “get high”).
format Online
Article
Text
id pubmed-3987019
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-39870192014-04-15 Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland Deline, Stéphane Baggio, Stéphanie Studer, Joseph N’Goran, Alexandra A. Dupuis, Marc Henchoz, Yves Mohler-Kuo, Meichun Daeppen, Jean-Bernard Gmel, Gerhard Int J Environ Res Public Health Article Objective: The present study investigates the use expectations, prevalence and frequency of neuroenhancement drug (ND) use among the Swiss male population, separating college students from others. Methods: Young Swiss men were invited to participate in the Cohort Study on Substance Use Risk Factors. A total of 5,967 participants responded to questions on six types of NDs (wakefulness medication, antidepressants, Alzheimer’s disease medication, Parkinson’s disease medication, attention deficit-hyperactivity disorder (ADHD) medication, and beta-blockers). The frequency of use depending on five expectations (to enhance wakefulness, attention, memory, concentration and stress reduction) was analyzed for a twelve-month period. Results: (1) About 3% of the sample indicated use of at least one ND; (2) ADHD medication was the most prevalent; (3) The type of ND preferred differed depending on academic status (4). Quantitatively, over the year, college student users used ND much less frequently than other users. Conclusions: Prevalence of ND use is low in Switzerland relative to other countries such as the United States. Patterns of ND use differed depending on academic status, suggesting that while college student ND users tended to do so rarely (probably to enhance cognitive abilities for exams), non-college male users used other NDs more frequently (probably to “get high”). MDPI 2014-03-12 2014-03 /pmc/articles/PMC3987019/ /pubmed/24625621 http://dx.doi.org/10.3390/ijerph110303032 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Deline, Stéphane
Baggio, Stéphanie
Studer, Joseph
N’Goran, Alexandra A.
Dupuis, Marc
Henchoz, Yves
Mohler-Kuo, Meichun
Daeppen, Jean-Bernard
Gmel, Gerhard
Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland
title Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland
title_full Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland
title_fullStr Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland
title_full_unstemmed Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland
title_short Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland
title_sort use of neuroenhancement drugs: prevalence, frequency and use expectations in switzerland
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987019/
https://www.ncbi.nlm.nih.gov/pubmed/24625621
http://dx.doi.org/10.3390/ijerph110303032
work_keys_str_mv AT delinestephane useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland
AT baggiostephanie useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland
AT studerjoseph useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland
AT ngoranalexandraa useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland
AT dupuismarc useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland
AT henchozyves useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland
AT mohlerkuomeichun useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland
AT daeppenjeanbernard useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland
AT gmelgerhard useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland